The Action addresses key barriers that currently limit the clinical uptake of pharmacogenomics in cardiovascular medicine. These include insufficient disease-specific evidence, lack of standardized methodologies, fragmented regulatory frameworks, limited integration into clinical workflows, and underutilization of artificial intelligence (AI) for large-scale genomic data analysis. The Action promotes the standardization of research and variant interpretation across Europe, ensuring comparability of studies and alignment of clinical guidelines.
Capacity building is a central component of the Action, with structured activities including training schools, webinars, workshops, and short-term scientific missions. These initiatives are designed to equip healthcare professionals and researchers with the knowledge and skills required to integrate pharmacogenomics into routine clinical practice, while fostering collaboration and knowledge exchange across Europe and beyond.
By promoting interdisciplinary collaboration, strengthening digital infrastructure, and supporting equitable access to personalized therapies, CardioPharmaGENET contributes to reducing adverse drug reactions, improving therapeutic outcomes, and enabling a transition from a “one-size-fits-all” approach toward precision cardiovascular medicine.